OR WAIT null SECS
© 2022 MJH Life Sciences and Optometry Times. All rights reserved.
© 2022 MJH Life Sciences™ and Optometry Times. All rights reserved.
The submission is supported by positive phase 3 data, which shows quick reversal of dilation and favorable safety and tolerability.
Rob Sambursky, MD, president of Verséa Ophthalmics, sat down with David Hutton of Ophthalmology Times to discuss 3 major developments in the company pipeline.
The #GlassesOn campaign promotes the benefits of eyewear for kids and invites support for the non-profit through Giving Tuesday on November 29th.
Ocuphire seeks to develop and commercialize Nyxol for the reversal of mydriasis, presbyopia and night vision disturbances.
The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.
Ocuphire submits new drug application for eye drops for reversal of mydriasis
Getting started: methods of initial scleral lens selection
What is presbyopia?
Case report: Combination treatment proves effective for choroidal metastasis from breast cancer patient